San Diego antifungal player nabs priority review for bloodstream infection treatment
Cidara Therapeutics wants to make its mark in the world of antifungals, and thanks to the FDA, it may get there soon.
The San Diego-based company announced Tuesday that the FDA has given priority review to its antifungal rezafungin for the treatment of candidemia and invasive candidiasis — common causes of serious bloodstream infections in hospitalized patients, per the CDC. No new therapies have been approved in over a decade for the two infections, the company said in a press statement. Rezafungin’s review deadline date is set for March 22, 2023.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.